A new trading day began on Tuesday, with Quince Therapeutics Inc (NASDAQ: QNCX) stock price down -4.12% from the previous day of trading, before settling in for the closing price of $3.4. QNCX’s price has ranged from $0.72 to $4.55 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 7.53% over the past five years. Meanwhile, its annual earnings per share averaged 16.54%. With a float of $48.30 million, this company’s outstanding shares have now reached $54.49 million.
Quince Therapeutics Inc (QNCX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Quince Therapeutics Inc is 13.25%, while institutional ownership is 20.78%. The most recent insider transaction that took place on Dec 26 ’25, was worth 173,211. Before that another transaction happened on Dec 26 ’25, when Company’s Director sold 50,000 for $3.47, making the entire transaction worth $173,500. This insider now owns 39,179 shares in total.
Quince Therapeutics Inc (QNCX) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.28 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.83% during the next five years compared to 7.53% growth over the previous five years of trading.
Quince Therapeutics Inc (NASDAQ: QNCX) Trading Performance Indicators
Here are Quince Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.22, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Quince Therapeutics Inc (QNCX)
Quince Therapeutics Inc (NASDAQ: QNCX) saw its 5-day average volume 0.29 million, a negative change from its year-to-date volume of 0.34 million. As of the previous 9 days, the stock’s Stochastic %D was 14.38%.
During the past 100 days, Quince Therapeutics Inc’s (QNCX) raw stochastic average was set at 58.52%, which indicates a significant increase from 5.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.32 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.67, while its 200-day Moving Average is $1.75. Nevertheless, the first resistance level for the watch stands at $3.37 in the near term. At $3.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.58. If the price goes on to break the first support level at $3.16, it is likely to go to the next support level at $3.07. The third support level lies at $2.95 if the price breaches the second support level.
Quince Therapeutics Inc (NASDAQ: QNCX) Key Stats
With a market capitalization of 181.52 million, the company has a total of 55,681K Shares Outstanding. Currently, annual sales are 0 K while annual income is -56,830 K. The company’s previous quarter sales were 0 K while its latest quarter income was -13,440 K.
